Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: Preparation and antitumor efficacy

Drug Development and Industrial Pharmacy

Volumn 34, Issue 8, 2008, Pages 834-839

  Yang, Zhiwen ^a   Yang, Muhua ^a   Peng, Jinnian ^a  

^a GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; Arsenic trioxide; Bovine serum albumin; Nanoparticles

Indexed keywords

ARSENIC TRIOXIDE; BOVINE SERUM ALBUMIN; DRUG CARRIER; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COACERVATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PROMYELOCYTIC LEUKEMIA; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG EVALUATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; NANOPARTICLES; OXIDES; PARTICLE SIZE; SERUM ALBUMIN, BOVINE;

EID: 49449091610     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040801926733     Document Type: Article

References (35)

1. Ambruosi, A., Khalansky, A. S., Yamamoto, H., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2006). Biodistribution of polysorbate 80-coated doxorubicin-loaded[14c]- poly (butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target, 14, 97-105.
2. Arnedo, A., Espuelas, S., & Irache, J. M. (2002). Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int. J. Pharm., 244, 59-72.
3. Arnedo, A., Irache, J. M., Merodio, M., & Espuelas Millán, M. S. (2004). Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J. Control. Release, 94, 217-227.
4. Barraud, L., Merle, P., Soma, E., Lefrancois, L., Guerret, S., Chevallier, M., Dubernet, C., Couvreur, P., Trepo, C., & Vitvitski L. (2005). Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol., 42, 736-743.
5. Bernardini, S., Nuccetelli, M., Noguera, N. I., Bellincampi, L., Lunghi, P., Bonati, A., Mann, K., Miller, W. H., Federici, G., & Lo Coco, F. (2006). Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann. Hematol., 85, 681-687.
6. Diaz, Z., Laurenzana, A., Mann, K. K., Bismar, T. A., Schipper, H. M., & Miller, W. H. (2007). Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia, 21, 2117-2127.
7. Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Jr., Kreuter, J., & Langer, K. (2007). Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm., 341, 207-214.
8. Eatock, M., Church, N., Harris, R., Angerson, W., McArdle, C., French, R., & Twelves, C. (1999). Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule. Invest. New Drugs, 17, 111-120.
9. Evens, A. M., Tallman, M. S., & Gartenhaus, R. B. (2004). The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future. Leuk. Res., 28, 891-900.
10. Illum, L., Davis, R. M., & Wilson, C. G. (1982). Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm., 2, 135-146.
11. Irache, J. M., Merodio, M., Arnedo, A., Camapanero, M. A., Mirshahi, M., & Espuelas, S. (2005). Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini. Rev. Med. Chem, 5, 293-305.
12. Jiang, X. H., Wong, B. C., Yuen, S. T., Jiang, S. H., Cho, C. H., Lai, K. C., Lin, M. C., Kung, H. F., & Lam, S. K. (2001). Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int. J. Cancer, 91, 173-179.
13. Labib, A., Lenaerts, V., Chouinard, F., Leroux, J. C., Ouellet, R., & van Lier, J. E. (1991). Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm. Res., 8, 1027-1031.
14. Lemarie, A., Morzadec, C., Bourdonnay, E., Fardel, O., & Vernhet, L. (2006). Human macrophages constitute targets for immunotoxic inorganic arsenic. J. Immunol., 177, 3019-3027.
15. Li, F. Q., Su, H., Wang, J., Liu, J. Y., Zhu, Q. G., Fei, Y. B., Pan, Y. H., & Hu J. H. (2007). Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int. J. Pharm., 11, 274-282.
16. Lin, W., Coombes, A. G., Davies, M. C., Davis, S. S., & Illum, L. (1993). Preparation of Sub-100 nm human serum albumin nanospheres using a ph-coacervation method. J. Drug Targeting., 1, 237-243.
17. Liu, P., & Han, Z. C. (2003). Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies. Int. J. Hematol., 78, 32-39.
18. Liu, B., Pan, S., Dong, X., Qiao, H., Jiang, H., Krissansen, G. W., & Sun, X. (2006). Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci., 97, 675-681.
19. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release, 65, 271-284.
20. Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R. V., Srivastava, V. M., Srivastava, A., & Chandy, M. (2006). Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood, 107, 2627-2632.
21. Moghimi, S. M., Hedeman, H., Muir, I. S., Illum, L., & Davis, S. S. (1993). An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta, 3, 233-240.
22. Moghimi, S. M., Porter, C. J., Muir, I. S., Illum, L., & Davis, S. S. (1999). Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun., 127, 861-866.
23. Park, J. W., Choi, Y. J., Jang, M. A., Baek, S. H., Lim, J. H., Passaniti, T., & Kwon, T. K. (2001). Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun., 286, 726-734.
24. Porter, C. J., Moghimi, S. M., Illum, L., & Davis S. S. (1992). The polyoxyethylene/polyoxy-propylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett., 305, 62-66.
25. Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000). Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia, 2, 306-314.
26. Sahu, G. R., & Jena, R. K. (2005). Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia. Am. J. Hematol., 78, 113-116.
27. Santhi, K., Dhanaraj, S. A., Joseph, V., Ponnusankar, S., & Suresh, B. A. (2002). Study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil. Drug Dev. Ind. Pharm., 28, 1171-1179.
28. Santhi, K., Dhanaraj, S. A., Koshy, M., Ponnusankar, S., & Suresh, B. (2000). Study of bio- distribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev. Ind. Pharm., 26, 1293-1296.
29. Siu, C. W., Au, W. Y., Yung, C., Kumana, C. R., Lau, C. P., Kwong, Y. L., & Tse, H. F. (2006). Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety. Blood, 108, 103-106.
30. Steiniger, S. C., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., & Gelperina S. E. (2004). Chemotherapy of glioblastoma in rats using doxorubicinloaded nanoparticles. Int. J. Cancer, 109, 759-767.
31. Verstovsek, S., Giles, F., Quintás-Cardama, A., Perez, N., Ravandi-Kashani, F., Beran, M., Freireich, E., & Kantarjian, H. (2006). Arsenic derivatives in hematologic malignancies: A role beyond acute promyelocytic leukemia. Hematol. Oncol., 24, 181-188.
32. Yoo, H. S., Oh, J. E., Lee, K. H., & Park, T. G. (1999). Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res., 16, 1114-1118.
33. Zhang, L., Hou, S., Mao, S., Wei, D., Song, X., & Lu, Y. (2004). Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int. J. Pharm., 287, 155-162.
34. Zhou, J., Zeng, F. Q., Li, C., Tong, Q. S., Gao, X., Xie, S. S., & Yu, L. Z. (2005). Preparation of arsenic trioxide-loaded albuminutes immuno-nanospheres and its specific killing effect on bladder cancer cell in vitro. Chin. Med. J (Engl)., 118, 50-55.
35. Zhu, Q., Zhang, J. W., Zhu, H. Q., Shen, Y. L., Flexor, M., Jia, P. M., Yu, Y., Cai, X., Waxman, S., Lanotte, M., Chen, S. J., Chen, Z., & Tong, J. H. (2002). Synergic effects of arsenictrioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood, 99, 1014-1022.